Athanase Innovation ABOMXSTO: ATIN

ATIN: Net sales grew but operating losses widened in Q2 2025, driven by negative securities value changes

Jul 11, 2025 at 2:31 AM EDT · Issued by Athanase Innovation AB

On 6ix: 6ix.com/news/atin-net-sales-grew-but-operating-losses-widened-in-q2-2025-driven-by-negative-securities-value-changes

Q2 2025 saw net sales rise to SEK 5.4m, but operating losses deepened to SEK -27.2m, with negative value changes in securities. Ivisys drove all sales, while Flyttsmart and Lifesum showed strong growth amid challenging market conditions.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Athanase Innovation AB on 6ix

Earlier from Athanase Innovation

ATIN: Sharp drop in sales and earnings; Ivisys spin-off and strong Zalaris, Pace growthMay 6, 2025
ATIN: Revenue surged on Ivisys growth; major capital return and Ivisys spin-off plannedFeb 21, 2025
ATIN: Q3 sales soared but losses deepened; board proposes share redemption and delistingNov 5, 2024
ATIN: Q2 saw higher revenue, strong value gains, and improved EBIT, led by Ivisys and ZalarisJul 12, 2024

Later from Athanase Innovation

ATIN: Sales and earnings fell, but portfolio companies delivered strong growth amid legal challengesNov 4, 2025
ATIN: Lower revenue and higher costs led to a larger loss, but portfolio growth and spin-off plans advanceFeb 20
Athanase Innovation To Accept Public Takeover Bid Submitted For ZalarisMar 13
Athanase Innovation Portfolio Company Ivisys Has Reached Settlement In Patent Dispute With ChepApr 13
ATIN: Q1 2026 saw lower revenue, stable cash, and value gains from listed holdings despite operating lossMay 5

All Athanase Innovation news releases

Follow Athanase Innovation into a list and get an email when it puts out news.

Follow Athanase Innovation